Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study findings from Y. Laplante et al provide new insights into breast cancer
May 28th, 2009
"We investigated the relative involvement of three reductive 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) isoforms, namely types 1, 7 and 12, in the formation of potent estrogen estradiol (E2) in 10 human breast cancer cell lines (T-47D, MCF-7, ZR-75-1, CAMA-1, BT-20, BRC-17, BRC-31, BRC-32, BRC-36 and BRN-196) and also in 1 choriocarcinoma cell line (JEG-3) using selective inhibitors. In T-47D, BT-20 and JEG-3 cells, a 17 beta-HSD1 inhibitor almost completely inhibited the formation of E2 at 1 mc M from 60 nM of estrone (E1) (98%, 91% and 90%, respectively), whereas no significant inhibition of E2 formation was obtained using inhibitors of types 7 and 12," scientists writing in the...
Source: Women's Health Weekly (2009-05-28)
|
